vs
Inotiv, Inc.（NOTV）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Inotiv, Inc.的1.1倍（$127.1M vs $120.9M），再鼎医药同比增速更快（17.1% vs 0.8%），Inotiv, Inc.自由现金流更多（$-10.6M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 0.8%）
Inotiv公司是一家注册于美国印第安纳州的合同研究组织，总部位于该州拉斐特市。公司设有两大核心业务板块：发现与安全评估业务（DSA）以及研究模型与服务业务（RMS），可为小分子候选药物、生物治疗产品及生物医疗设备提供安全评估、分析、代谢研究、CMC及法规咨询等药物开发与环境科学相关服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
NOTV vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.1倍
$120.9M
营收增速更快
ZLAB
高出16.3%
0.8%
自由现金流更多
NOTV
多$16.1M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
0.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $120.9M | $127.1M |
| 净利润 | $-28.4M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | -13.5% | -54.6% |
| 净利率 | -23.5% | — |
| 营收同比 | 0.8% | 17.1% |
| 净利润同比 | -2.7% | — |
| 每股收益（稀释后） | $-0.83 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NOTVZLAB
| Q4 25 | $120.9M | $127.1M | ||
| Q3 25 | $138.1M | $115.4M | ||
| Q2 25 | $130.7M | $109.1M | ||
| Q1 25 | $124.3M | $105.7M | ||
| Q4 24 | $119.9M | $108.5M | ||
| Q3 24 | $130.4M | $101.8M | ||
| Q2 24 | $105.8M | $100.1M | ||
| Q1 24 | $119.0M | $87.1M |
净利润NOTVZLAB
| Q4 25 | $-28.4M | — | ||
| Q3 25 | $-8.6M | $-36.0M | ||
| Q2 25 | $-17.6M | $-40.7M | ||
| Q1 25 | $-14.9M | $-48.4M | ||
| Q4 24 | $-27.6M | — | ||
| Q3 24 | $-18.9M | $-41.7M | ||
| Q2 24 | $-26.1M | $-80.3M | ||
| Q1 24 | $-48.1M | $-53.5M |
毛利率NOTVZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率NOTVZLAB
| Q4 25 | -13.5% | -54.6% | ||
| Q3 25 | -4.9% | -42.3% | ||
| Q2 25 | -4.3% | -50.3% | ||
| Q1 25 | -2.4% | -53.3% | ||
| Q4 24 | -12.9% | -62.6% | ||
| Q3 24 | -10.1% | -66.6% | ||
| Q2 24 | -19.6% | -76.0% | ||
| Q1 24 | -36.2% | -80.7% |
净利率NOTVZLAB
| Q4 25 | -23.5% | — | ||
| Q3 25 | -6.2% | -31.2% | ||
| Q2 25 | -13.5% | -37.3% | ||
| Q1 25 | -12.0% | -45.8% | ||
| Q4 24 | -23.0% | — | ||
| Q3 24 | -14.5% | -40.9% | ||
| Q2 24 | -24.7% | -80.2% | ||
| Q1 24 | -40.4% | -61.4% |
每股收益（稀释后）NOTVZLAB
| Q4 25 | $-0.83 | $-0.05 | ||
| Q3 25 | $-0.14 | $-0.03 | ||
| Q2 25 | $-0.51 | $-0.04 | ||
| Q1 25 | $-0.44 | $-0.04 | ||
| Q4 24 | $-1.02 | $-0.09 | ||
| Q3 24 | $-0.73 | $-0.04 | ||
| Q2 24 | $-1.00 | $-0.08 | ||
| Q1 24 | $-1.86 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.7M | $689.6M |
| 总债务越低越好 | $405.8M | — |
| 股东权益账面价值 | $109.0M | $715.5M |
| 总资产 | $734.3M | $1.2B |
| 负债/权益比越低杠杆越低 | 3.72× | — |
8季度趋势，按日历期对齐
现金及短期投资NOTVZLAB
| Q4 25 | $12.7M | $689.6M | ||
| Q3 25 | $21.7M | $717.2M | ||
| Q2 25 | $6.2M | $732.2M | ||
| Q1 25 | $19.3M | $757.3M | ||
| Q4 24 | $38.0M | $779.7M | ||
| Q3 24 | $21.4M | $616.1M | ||
| Q2 24 | $14.4M | $630.0M | ||
| Q1 24 | $32.7M | $650.8M |
总债务NOTVZLAB
| Q4 25 | $405.8M | — | ||
| Q3 25 | $402.1M | — | ||
| Q2 25 | $396.5M | — | ||
| Q1 25 | $399.5M | — | ||
| Q4 24 | $396.0M | — | ||
| Q3 24 | $393.3M | — | ||
| Q2 24 | $382.4M | — | ||
| Q1 24 | $380.6M | — |
股东权益NOTVZLAB
| Q4 25 | $109.0M | $715.5M | ||
| Q3 25 | $136.0M | $759.9M | ||
| Q2 25 | $143.8M | $791.7M | ||
| Q1 25 | $157.7M | $810.8M | ||
| Q4 24 | $169.8M | $840.9M | ||
| Q3 24 | $170.5M | $667.7M | ||
| Q2 24 | $182.1M | $704.2M | ||
| Q1 24 | $207.2M | $762.2M |
总资产NOTVZLAB
| Q4 25 | $734.3M | $1.2B | ||
| Q3 25 | $771.1M | $1.2B | ||
| Q2 25 | $759.7M | $1.2B | ||
| Q1 25 | $766.0M | $1.2B | ||
| Q4 24 | $772.9M | $1.2B | ||
| Q3 24 | $781.4M | $985.3M | ||
| Q2 24 | $774.6M | $987.4M | ||
| Q1 24 | $815.4M | $988.4M |
负债/权益比NOTVZLAB
| Q4 25 | 3.72× | — | ||
| Q3 25 | 2.96× | — | ||
| Q2 25 | 2.76× | — | ||
| Q1 25 | 2.53× | — | ||
| Q4 24 | 2.33× | — | ||
| Q3 24 | 2.31× | — | ||
| Q2 24 | 2.10× | — | ||
| Q1 24 | 1.84× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-10.6M | $-26.7M |
| 自由现金流率自由现金流/营收 | -8.8% | -21.0% |
| 资本支出强度资本支出/营收 | 4.3% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-28.7M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流NOTVZLAB
| Q4 25 | $-5.4M | $-26.0M | ||
| Q3 25 | $14.3M | $-32.0M | ||
| Q2 25 | $-7.4M | $-31.0M | ||
| Q1 25 | $-12.8M | $-61.7M | ||
| Q4 24 | $-4.5M | $-55.8M | ||
| Q3 24 | $-2.4M | $-26.8M | ||
| Q2 24 | $-14.8M | $-42.2M | ||
| Q1 24 | $16.9M | $-90.1M |
自由现金流NOTVZLAB
| Q4 25 | $-10.6M | $-26.7M | ||
| Q3 25 | $11.6M | $-35.0M | ||
| Q2 25 | $-11.5M | $-33.9M | ||
| Q1 25 | $-18.3M | $-63.2M | ||
| Q4 24 | $-9.0M | $-58.4M | ||
| Q3 24 | $-7.7M | $-28.2M | ||
| Q2 24 | $-19.2M | $-42.9M | ||
| Q1 24 | $9.9M | $-91.1M |
自由现金流率NOTVZLAB
| Q4 25 | -8.8% | -21.0% | ||
| Q3 25 | 8.4% | -30.4% | ||
| Q2 25 | -8.8% | -31.1% | ||
| Q1 25 | -14.7% | -59.9% | ||
| Q4 24 | -7.5% | -53.8% | ||
| Q3 24 | -5.9% | -27.7% | ||
| Q2 24 | -18.2% | -42.9% | ||
| Q1 24 | 8.3% | -104.5% |
资本支出强度NOTVZLAB
| Q4 25 | 4.3% | 0.5% | ||
| Q3 25 | 1.9% | 2.6% | ||
| Q2 25 | 3.1% | 2.6% | ||
| Q1 25 | 4.4% | 1.5% | ||
| Q4 24 | 3.7% | 2.4% | ||
| Q3 24 | 4.1% | 1.3% | ||
| Q2 24 | 4.2% | 0.7% | ||
| Q1 24 | 5.9% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NOTV
| Research Models And Services Segment | $72.9M | 60% |
| Discovery And Safety Assessment Segment | $48.0M | 40% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
